Wealth Enhancement Advisory Services LLC Purchases 13,194 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Wealth Enhancement Advisory Services LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 292,966 shares of the biopharmaceutical company's stock after buying an additional 13,194 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Gilead Sciences were worth $32,827,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Annis Gardner Whiting Capital Advisors LLC raised its holdings in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $35,000. Synergy Investment Management LLC acquired a new position in Gilead Sciences in the fourth quarter worth approximately $40,000. Lee Danner & Bass Inc. acquired a new position in Gilead Sciences in the fourth quarter worth approximately $41,000. Finally, Fourth Dimension Wealth LLC acquired a new position in Gilead Sciences in the fourth quarter worth approximately $54,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 0.5%

Shares of Gilead Sciences stock traded up $0.50 on Friday, hitting $108.50. 23,266,621 shares of the company traded hands, compared to its average volume of 7,661,575. The company has a 50-day moving average price of $106.16 and a 200 day moving average price of $102.81. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 12-month low of $66.01 and a 12-month high of $119.96. The company has a market cap of $134.97 billion, a PE ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the previous year, the company posted ($1.32) EPS. Gilead Sciences's revenue was down .3% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.91%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Analysts Set New Price Targets

Several research analysts have issued reports on GILD shares. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,500 shares of company stock valued at $5,236,245. Insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.